Added to YB: 2026-06-18
Pitch date: 2026-06-15
ANAB [bullish]
AnaptysBio, Inc.
-3.98%
current return
Author Info
Triple S is a professional special situations investor who shares ideas in their newsletter. Sign up for the newsletter.
Company Info
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States.
Market Cap
$1.7B
Pitch Price
$60.00
Price Target
80.00 (+39%)
Dividend
N/A
EV/EBITDA
38.05
P/E
-60.80
EV/Sales
7.18
Sector
Biotechnology
Category
special_situation
AnaptysBio, Inc. - $ANAB
ANAB: Pure-play royalty co post-pipeline spin (TRAX). ~$140M net cash, <$10M OpEx, <10 FTEs. Jemperli royalties 8-25% (sales $1.1B 2025, GSK guides $2.7B peak), patents mid-2030s. Sagard loan ($600M) repaid ~mid-2027 → cash flow explodes; 10x = $80/share min. Imsidolimab bonus stream. GSK Delaware lawsuit (trial next month): settlement likely (like 2020), nuclear case = drug reversion; downside protected as court already barred royalty cuts. Lotto ticket w/ floor.
Read full article (4 min)